Molecular Characterization and Antimicrobial Susceptibility of Nasal *Staphylococcus aureus* Isolates from a Chinese Medical College Campus

Jimei Du¹, Chun Chen², Baixing Ding³, Jinjing Tu², Zhiqiang Qin⁴, Chris Parsons⁴, Cassandra Salgado⁴, Qiangjun Cai¹, Yulong Song¹, Qiyu Bao¹, Liming Zhang⁶, Jingye Pan³, Liangxing Wang²*, Fangyou Yu⁵*

¹School of Laboratory Medicine, Wenzhou Medical College, Wenzhou, China, ²Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China, ³Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China, ⁴Division of Infectious Diseases, Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States of America, ⁵Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China, ⁶Department of Clinical Laboratory, Taizhou Center Hospital, Taizhou, China

Abstract

*Staphylococcus aureus* colonization and infection occur more commonly among persons living or working in crowded conditions, but characterization of *S. aureus* colonization within medical communities in China is lacking. A total of 144 (15.4%, 144/935) *S. aureus* isolates, including 28 (3.0%, 28/935) MRSA isolates, were recovered from the nares of 935 healthy human volunteers residing on a Chinese medical college campus. All *S. aureus* isolates were susceptible to vancomycin, quinupristin/dalfopristin and linezolid but the majority were resistant to penicillin (96.5%), ampicillin/sulbactam (83.3%) and trimethoprim/sulfamethoxazole (93.1%). 82%, (23/28) of the MRSA isolates and 66% (77/116) of the MSSA isolates were resistant to multiple antibiotics, and 3 MRSA isolates were resistant to mupirocin—an agent commonly used for nasal decolonization. 16 different sequence types (STs), as well as SCCmec genes II, III, IVd, and V, were represented among MRSA isolates. We also identified, for the first time, two novel STs (ST1778 and ST1779) and 5 novel spa types for MRSA. MRSA isolates were distributed in different sporadic clones, and ST59-MRSA-VId-t437 was found within 3 MRSA isolates. Moreover, one isolate with multidrug resistance belonging to ST398-MRSA-V-t571 associated with animal infections was identified, and 3 isolates distributed in three different clones harbored PVL genes. Collectively, these data indicate a high prevalence of nasal MRSA carriage and molecular heterogeneity of *S. aureus* isolates among persons residing on a Chinese medical college campus. Identification of epidemic MRSA clones associated with community infection supports the need for more effective infection control measures to reduce nasal carriage and prevent dissemination of MRSA to hospitalized patients and healthcare workers in this community.

Introduction

*Staphylococcus aureus* is one of the most prevalent and clinically significant pathogens worldwide, causing a variety of illnesses ranging from benign, superficial skin eruptions to life-threatening infections with bacteraemia, endocarditis, pneumonia and toxic shock syndrome [1]. Since methicillin-resistant *S. aureus* (MRSA) was first identified in 1961, it has become the most common cause of nosocomial and community infections worldwide [2]. The recent emergence of highly virulent community-associated MRSA (CA-MRSA) isolates which cause disease in individuals with no apparent risk factors for hospital acquisition of MRSA has raised widespread concern over how CA-MRSA is transmitted in the community setting [3,4].

*S. aureus* is a member of commensal microflora and readily colonizes the anterior nares in humans. Many infections caused by *S. aureus* occur in persons with prior nasal carriage [5], and this carriage is an important risk factor for nosocomial *S. aureus* infection in patients undergoing surgery, hemodialysis, implantation of intravascular devices, and among HIV-infected patients [6]. One study revealed that nasal carriage of *S. aureus* is an important source of *S. aureus* bacteraemia [7], and eliminating nasal carriage of *S. aureus* may prevent systemic *S. aureus* infection [7]. Determination of the prevalence of *S. aureus* nasal carriage, as well as antimicrobial resistance profiles and molecular typing for nasal *S. aureus* isolates, in healthy populations is beneficial for identifying risk factors associated with *S. aureus* infection [8,9,10]. Molecular typing of *S. aureus* is also helpful for supporting infection control measures, investigating suspected outbreaks and preventing nosocomial transmission [11]. Identification of (Panton-Valentine Leukocidin) PVL genes, pulsed-field gel electrophoresis (PFGE), staphylococcal cassette chromosome mec (SCCmec) typing, spa typing, and multilocus sequence typing (MLST) have been used to monitor the evolutionary process of pandemic clones [12]. However, studies characterizing *S. aureus* isolates in China have largely focused on isolates recovered from clinical specimens in the...
context of clinical disease. One surveillance study performed in China showed that 63% of S. aureus isolates were MRSA, including 77% of nosocomial isolates and 43% of community isolates [13]. In addition, two major epidemic MRSA clones, ST239-MRSA-SCCmec type III and ST5-MRSA-SCCmec type II, are distributed across China in unique geographic patterns [14]. These data suggest that dissemination of virulent MRSA clones among healthy persons in China may contribute to the presence of clinically significant MRSA infections in some locations. To our knowledge, there are limited published studies characterizing MRSA isolates recovered from nares of healthy individuals in China who work and reside in the health care setting. Therefore, we sought to determine the prevalence, antimicrobial resistance profiles, and molecular characteristics of nasal S. aureus isolates from students on a large medical college campus in China.

Materials and Methods

Isolation and identification of nasal S. aureus isolates

935 volunteers from the campus of Wenzhou Medical College in Wenzhou, Southeast China without symptoms or signs of clinical illness were enrolled in the study over a one-month time period. The healthy volunteers included had not used antibiotics in past two months. Samples were collected from both anterior nares of volunteers by rotating a sterile polyester fiber-tipped swab moistened with sterile saline. Swabs were placed in 3 mL of Luria-Bertani broth and transported to the Department of Clinical Microbiology of the first Affiliated Hospital of Wenzhou Medical College. Gram-positive, catalase-positive, coagulase-positive isolates were confirmed as S. aureus using a Vitek-60 microbiology analyzer (bioMe’rieux, Marcy l’Etoile, France). The Ethics Committee of the first Affiliated Hospital of Wenzhou Medical College exempted this study from review because the present study focused on bacteria.

Susceptibility testing

S. aureus susceptibility to penicillin (10 μg), ampicillin/sulbactam (20/10 μg), cefazolin (30 μg), vancomycin (30 μg), erythromycin (15 μg), clindamycin (2 μg), rifampicin (5 μg), linezolid (30 μg), mupirocin (5 μg), quinupristin/dalfopristin (15 μg), tetracycline (30 μg), trimethoprim/sulfamethoxazole (1.25/25.75 μg), gentamicin (10 μg), ciprofloxacin (5 μg), and levofloxacin (5 μg) were determined using the disk diffusion method in accordance with standards recommended by the Clinical and Laboratory Standards Institute (CLSI) [15]. All disks were obtained from Oxoid Ltd., and S. aureus ATCC 25923 was used as a quality control strain. Susceptibility of S. aureus to mupirocin was also determined using disk diffusion, with a zone diameter ≥14 mm using a 5-μg disc indicating susceptibility as described previously [16]. MICs of mupirocin for mupirocin-resistant isolates were further determined by the agar dilution method in accordance with the CLSI guidelines [15]. mupA was detected among mupirocin-resistant isolates as described previously[17].

DNA Extraction

S. aureus isolates were cultured on blood agar overnight. Three to four bacterial colonies were suspended in 150 μL sterile distilled water with lysostaphin (1 mg/mL) (Sangon, China) and incubated at 37°C for 30 min. DNA was extracted using the Genomic DNA Extraction kit according to the manufacturer’s instructions (Sangon, China). DNA was stored at −20°C and prepared for PCR amplification.

Detection of MRSA and PVL genes

A multiplex PCR protocol described previously was used for simultaneous amplification of mecA, 16S rRNA, and PVL genes [18]. Isolates harboring mecA were confirmed as MRSA using MRSA N315 as a positive control strain.

SCCmec typing

SCCmec typing of MRSA isolates was performed using eight unique and specific pairs of primers for SCCmec types and subtypes I, II, III, IVa, IVb, IVc, IVd, and V as described previously [19]. The MRSA isolates with unexpected fragments or lacking fragments by multiplex PCR were defined as non-typeable (NT). MRSA NCTC 10442 (SCCmecI), MRSA N315 (SCCmecII), MRSA 85/2082 (SCCmecIII), MRSA JGSC 4744 (SCCmecIV) and MRSA WZ153 (SCCmecV) were used for positive controls.

spa typing

The spa variable repeat region from each MRSA isolate was amplified by simplex PCR oligonucleotide primers as previously described [20,21]. Purified spa PCR products were sequenced, and spa types were assigned by using the spa database website (http://www.ridom.de/spaserver).

Multilocus sequence typing (MLST)

MLST of MRSA isolates was conducted through amplification of internal fragments of the seven housekeeping genes of S. aureus as described previously [22]. Following purification and sequencing of these genes, allele quantification and sequence typing were assigned using a well-characterized online database (http://saureus.mlst.net/). The DNA sequences of novel STs were verified by Pro. Enright and deposited in MLST database.

Results

A total of 144 S. aureus isolates were isolated from the nares of the 935 volunteers in the study. The nasal carriage rate of S. aureus was 15.4% (144/935). 19.4% (28/144) of S. aureus isolates were identified as MRSA. The prevalence of nasal MRSA carriage was 3.0% (28/995). The resistance profiles of MRSA, MSSA and S. aureus isolates to antimicrobials tested were listed in Table 1. All S. aureus isolates tested were susceptible to vancomycin, quinupristin/dalfopristin and linezolid. The majority of S. aureus isolates were resistant to penicillin (96.5%), ampicillin/sulbactam (83.3%) and trimethoprim/sulfamethoxazole (93.1%). Isolates displayed complete or intermediate levels of resistance to gentamicin (16.0% and 18.1%), tetracycline (28.5% and 16.7%), ciprofloxacin (23.6% and 22.2%), clindamycin (31.2% and 23.6%) and erythromycin (52.1% and 30.6%). The resistance rates of MRSA isolates to gentamicin, ciprofloxacin, levofloxacin, erythromycin and clindamycin were significantly higher than those among MSSA isolates (Table 1). However, the intermediate resistance rates of MSSA isolates to gentamicin, tetracycline, erythromycin, clindamycin and rifampicin were higher than for MRSA isolates (Table 1). 82.1% (23/28) of MRSA isolates and 66.4% (77/116) of MSSA isolates were resistant to at least 3 different antimicrobials tested. Three MRSA isolates with no zone of inhibition to mupirocin (2.1%, 3/144) were resistant to mupirocin. The mupirocin MICs for the 3 MRSA isolates were >512 μg/mL determined by agar dilution method. The 3 MRSA isolates were positive for mupA detected by PCR.

MRSA isolates expressing SCCmec V (15 isolates), SCCmec II (5 isolates), SCCmec III (4 isolates) and SCCmec IV (3 isolates) were identified (Table 2). The remaining isolate was non-typeable by multiplex PCR. MLST revealed 16 different sequence types (STs)
for 22 of the MRSA isolates, including ST6, ST15, ST25, ST59, ST38, ST188, ST438, ST398, ST943, ST946, ST1295, ST1556, ST1623, ST1778 and ST1779, were also identified. Since at least one of the 7 housekeeping genes for MLST typing could not be amplified among the remaining 6 MRSA isolates, STs for these isolates were not available. The STs most commonly identified were ST59 (4 isolates), ST25 (3 isolates), ST188 (2 isolates) and ST438 (2 isolates). Two novel STs recently deposited in the MLST database (http://saureus.mlst.net/), ST1778 and ST438, were also identified.

19 MRSA isolates were assigned 12 previously characterized spa types, and 5 other isolates were assigned 5 novel spa types (Table 2). spa typing could not be assigned for the remaining 5 MRSA isolates. Furthermore, MRSA isolates were distributed among different sporadic clones. ST59-MRSA-Vid-spa t437 was identified for 3 MRSA isolates. Three isolates, representing ST1556-MRSA-V-t437, ST25-MRSA-NT-t078 and ST338-MRSA-V-t163 clones, harbored PVL genes. One isolate exhibiting multidrug resistance was characterized as an ST398-MRSA-V-spa t571 clone. Three MRSA isolates typed as ST25 exhibited different spa types and SCCmec types and belonged to different clones. Although 2 ST188 MRSA isolates harbored SCCmec (V), these isolates exhibited two different spa types, t189 and t1751.

### Discussion

The prevalence of *S. aureus* nasal carriage among healthy adults ranges from approximately 20% to 30%, with higher prevalences in overcrowded populations [5,6,8,23]. In the United States, a national population-based survey conducted over a 3-year period revealed nasal *S. aureus* colonization for 32% of study participants [24]. In contrast, a relatively low rate of nasal *S. aureus* carriage (6.3%) was found for children under the age of 5 in India [25]. The prevalence of nasal colonization with *S. aureus* in our study was 15.4%, a prevalence similar to that observed (16%) for a suburban military camp cohort in Beijing, China [26]. However, the prevalence of nasal MRSA carriage in our study (3.0%) was higher than prevalences previously reported for cohorts from developed countries, including the United States [24,27,28]. Furthermore, no nasal MRSA colonization was found among Chinese healthy military volunteers in another study [26]. In contrast, a relatively high prevalence of MRSA colonization was found (11.6%) for a cohort of healthy children aged ≤14 years in community settings in Taiwan over a 5-year period [29]. These data indicate that MRSA colonization varies significantly, even within similar populations in developed countries. The isolation of nasal *S. aureus* with a single sample may result in underestimating the number of intermittent carriers. In order to improving the isolation of nasal *S. aureus*, multiple nasal swabs should be taken from both anterior nares of volunteers. Additional studies are needed to clarify relationships between MRSA colonization, age, general antibiotic use, and other variables within overcrowded populations at higher risk for MRSA infections.

Our study revealed that 93% of nasal *S. aureus* isolates were resistant to trimethoprim-sulfamethoxazole, with MSSA isolates exhibiting the highest rates of resistance. These data contradict several studies reporting low rates of resistance to trimethoprim-sulfamethoxazole for *S. aureus* isolates recovered from the nares [29–31]. For example, in one study of 371 nasal *S. aureus* isolates, only 7 (1.9%) were resistant to trimethoprim-sulfamethoxazole [29]. Our data are not in agreement with another study reporting trimethoprim-sulfamethoxazole susceptibility rates of 78.6% and 95.3%, for MRSA and MSSA isolates, respectively, recovered from patients in 12 cities across China [30]. Similar to other surveillance studies [13,30], we found high rates of resistance for nasal *S. aureus* isolates to penicillin, ampicillin/sulbactam and erythromycin, and no discernable resistance of these isolates to vancomycin, quinupristin/dalfopristin or linezolid. Mupirocin is used commonly for treating MRSA skin and soft-tissue infections and eliminating nasal MRSA colonization among patients and medical staff. Our study indicated that 10.7% of nasal MRSA isolates were resistant to mupirocin, in agreement with mupirocin resistance rates observed for MRSA isolates recovered in the context of clinical infection in another study conducted in China.

### Table 1. Antimicrobial susceptibility profiles of MRSA, MSSA and *S. aureus* nasal isolates.

|                      | MRSA (n = 28)* | MSSA(n = 116) | *S. aureus*(n = 144) |
|----------------------|---------------|--------------|----------------------|
|                      | R(%)          | I(%)         | R(%)                 | I(%)             | R(%)             | I(%)             |
| Penicillin           | 100           | 95.7         | 96.5                 | 0                | 95.5             | 0                |
| Amoxicillin/Clavulanate | 92.9         | 82.8         | 83.3                 | 1.4              | 83.6             | 1.4              |
| Cefazolin            | 7.1           | 7.1          | 0.9                  | 0                | 2.1              | 1.4              |
| Trimethoprin/sulfamethoxazole | 85.7 | 94.8 | 93.1                 | 0                | 93.1             | 0                |
| Gentamicin           | 28.6          | 7.1          | 12.9                 | 20.7             | 16.0             | 18.1             |
| Tetracycline         | 28.6          | 0            | 28.4                 | 20.7             | 28.5             | 16.7             |
| Vancocin             | 0             | 0            | 0                    | 0                | 0                | 0                |
| Ciprofloxacin        | 53.6          | 17.9         | 16.4                 | 23.3             | 23.6             | 22.2             |
| Levofloxacin         | 39.3          | 17.9         | 6.9                  | 6.0              | 13.2             | 8.3              |
| Erythromycin         | 75            | 14.3         | 46.6                 | 34.5             | 52.1             | 30.6             |
| Clindamycin          | 53.6          | 10.7         | 25.9                 | 27.6             | 31.2             | 23.6             |
| Rifampicin           | 3.6           | 0            | 6.9                  | 8.6              | 6.3              | 6.9              |
| Linezolid            | 0             | 0            | 0                    | 0                | 0                | 0                |
| Dalfopristin/Quinupristin | 0     | 0            | 0                    | 0                | 0                | 0                |
| Mupirocin            | 10.7          | 0            | 0                    | 0                | 2.1              | 0                |

* R, resistance; I, intermediate susceptibility.

doi:10.1371/journal.pone.0027328.t001
Wenzhou, China [31]. Therefore, different decolonization strategies including mupirocin may prove more successful for reducing nasal MRSA carriage among members of the Chinese medical community, and possibly Chinese hospital-associated MRSA infections.

Understanding the molecular characteristics of MRSA isolates recovered from healthy individuals may facilitate a better understanding of mechanisms for geographic distribution of MRSA in certain populations, as well as the population-based risk for aggressive community-acquired MRSA infections. CA-MRSA isolates from different geographic areas have demonstrated significant genetic diversity [12]. The vast majority of CA-MRSA isolates worldwide belong to 5 clones: pandemic clone USA300 (ST18), European clone (ST80), midwest clone (ST1), southwest pacific oceanic clone (ST30) and pacific clone (ST39) [12]. Studies performed in Taiwan indicate that ST39 was the most common MLST type for MRSA isolates associated with community-acquired infections and nasal colonization, particularly pediatric infections [29,32,33,34]. The majority (90%) of MRSA isolates recovered from healthy individuals over a 5-year period in Taiwan were clustered into minor variants of two clonal types, ST59 and ST339 [29]. However, the nasal MRSA isolates recovered in our study showed considerable heterogeneity, with ST59 and ST339 accounting for only 14.3% and 3.6% of STs, respectively. One recently published study found that among MRSA isolates associated with pediatric infections on the Chinese mainland, ST39-MRSA-SCCmecIV-t1437 was the most common clone identified (59%), followed by ST1 (8%) and ST338 (8%) [35]. ST39-MRSA-SCCmecIV-t1437 and ST338-MRSA-SCCmecV-t163 clones were identified from healthy volunteers in our study, indicating that these two clones may contribute to community infection and dissemination among hospital employees. HA-MRSA infections are caused by a relatively small number of epidemic MRSA clones [36], and ST239-MRSA-SCCmec type III and ST5-MRSA-SCCmec type II are two major epidemic MRSA clones identified in China [14]. Interestingly, these two clones were not isolated in our study. In previous studies published by our group [37,38], ST38 was the most common clone identified among PVL-positive isolates. In the present study, ST38-MRSA-SCCmecV was identified for only one PVL-negative nasal MRSA isolate. Whether CA-MRSA clones identified within the nares of healthy individuals are responsible for clinical infections caused by CA-MRSA in China remains to be determined.

CA-MRSA pathogenesis has been linked to carriage of PVL encoding genes [39]. Relatively high prevalences of PVL gene expression were also found among nasal S. aureus isolates in Chengdu, China (22%) [41], and Taiwan (19.1%) [40,41]. We noted a somewhat lower prevalence (11%) of PVL gene expression for nasal MRSA isolates in our study. Whether a higher prevalence of PVL expression for nasal S. aureus isolates portends a higher rate of clinical S. aureus infections, and more severe CA-MRSA infections, in Chinese populations remains to be determined. Epidemiologic studies tracking incident CA-MRSA infections in our institution, and determining whether infections caused by PVL-expressing CA-MRSA isolates arise in persons in contact with healthy volunteers in our study harboring these isolates, is ongoing.

ST398-MRSA is usually associated with animal infection, especially in pigs [42], and persons in close contact with animals are more likely to harbor ST398-MRSA isolates [37,43,44,45]. Recently published data suggest that human infections caused by MRSA-ST398 are increasing [37,43,44,45]. One nasal MRSA isolate belonging to ST398-MRSA-V-spa t571 was found in our study. It would be interesting to determine whether medical students performing cadaveric procedures using animals are more likely to harbor ST398-MRSA.

In conclusion, we found a relatively high prevalence of nasal MRSA carriage within healthy persons from a Chinese medical college campus. Among these nasal MRSA isolates, epidemic clones associated with community infection were found, supporting policies for reducing nasal carriage in order to prevent spread of MRSA to community members and hospitalized patients. Moreover, antibiotic resistance patterns for these isolates indicate that unique decolonization strategies may be needed.

Acknowledgments

We gratefully acknowledge the students from Wenzhou Medical College, Zhongyong Wang and Liqing Zhu, for participation in the collection of nasal specimens and Yuanyuan Lu for performing experiment. We are also grateful to T. Ito for the kind gift of MRSA NCTC 10442 (SCCmec I), MRSA N315 (SCCmec II), MRSA65/2002 (SCCmec III), and MRSA JCSC4744 (SCCmec IV).

Table 2. Molecular characterization of MRSA nasal isolates and their antibiotic resistance profiles.

| SCCmec | spa type | STs | Resistance profilea | pvlb |
|--------|----------|-----|---------------------|-----|
| N2     | V        | t437 | 1556               | P, AML, CIP + |
| N18    | V        | t143 | 338                | P, AML, STX, E, DA, TE, RD + |
| N30    | VId      | t437 | 59                 | P, AML, STX, E, KE – |
| N39    | V        | NT   | 438                | P, AML, STX, E, DA, CIP, LEV – |
| N44    | V        | t289 | 943                | P, AML, STX, E – |
| N54    | V        | new  | 88                 | P, AML, LE, DA, CIP, LEV, CN, TE – |
| N55    | VId      | t437 | 59                 | P, AML, DA – |
| N57    | V        | t177 | 438                | P, AML, STX, E, DA, CIP, LEV, CN, TE – |
| N58    | II       | new  | NTa                | P, AML, STX, E, DA, CIP, CN, TE – |
| N77    | II       | new  | NT                 | P, AML, STX, E, DA, CIP, LEV, CN, TE – |
| N86    | V        | t571 | 398                | P, AML, STX, E, DA, CIP, CN – |
| N91    | III      | t304 | 59                 | P, AML, STX – |
| N92    | III      | t304 | NT                 | P, AML, STX, E, DA, CIP, LEV, MUP – |
| N97    | VId      | t437 | 59                 | P, AML, STX, E, DA, TE – |
| N98    | V        | new  | 946                | P, AML, STX, E, DA – |
| N99    | III      | NT   | 6                  | P, SXT, DA – |
| N108   | V        | t189 | 188                | P, AML, STX – |
| N112   | II       | t081 | NT                 | P, AML, STX, E, DA, CIP, LEV – |
| N114   | V        | t081 | 25                 | P, AML, STX, E, CN, TE – |
| N121   | V        | NT   | 1778               | P, AML, STX, E, DA, CIP, LEV, CN, TE – |
| N123   | V        | NT   | 1623               | P, AML, STX, CIP, CN, KZ – |
| N128   | NT       | t078 | 25                 | P, AML, STX – |
| N135   | III      | t062 | 1779               | P, AML, CIP, LEV – |
| N145   | V        | t1751| 188                | P, AML, STX, E, CIP, LEV – |
| N154   | V        | t087 | 25                 | P, AML – |
| N165   | V        | new  | 1285               | P, SXT – |
| N167   | II       | t5196| 15                 | P, AML, STX, E, CIP, LEV – |
| N168   | II       | t1751| NT                 | P, AML, STX, E, DA, CIP, LEV, MUP – |

*aP, penicillin; AML, Ampicillin/Sulbactam; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim/sulfamethoxazole; E, erythromycin; DA, clindamycin; RD, rifampicin; CN, gentamycin; KZ, cefazolin; TE, tetracycline; MUP, mupirocin.

bPVL negative; +, pVL positive.

NT, not typeable.

doi:10.1371/journal.pone.0027328.t002

Nasal Staphylococcus aureus Isolates from China
Conceived and designed the experiments: FY LB LJP LW. Performed the experiments: JD CC QC YS JT BD. Analyzed the data: ZQ CP CS.

Contributed reagents/materials/analysis tools: BD. Wrote the paper: FY. Revised the manuscript critically for important intellectual content: ZQ CP CS.

References

1. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339: 520–532.
2. Deresinski S (2005) Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 40: 562–573.
3. Taiwo SB (2009) Methicillin resistance in Staphylococcus aureus: a review of the molecular epidemiology, clinical significance and laboratory detection methods. West Afr J Med 28: 211–290.
4. Cohen PR (2007) Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol 8: 259–270.
5. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, et al. (2005) The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5: 751–762.
6. Kluytmans J, van Belkum A, Verbrugh H (1997) Nasal carriage of Staphylococcus aureus: underlying mechanisms, and associated risks. Clin Microbiol Rev 10: 565–520.
7. von Eiff C, Becker K, Machka K, Stammer H, Peters G (2001) Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 344: 11–16.
8. Bischoff WE, Wallis ML, Tucker KB, Reboussin BA, Sherertz RJ (2004) Methicillin-resistant Staphylococcus aureus nasal carriage in a student community: prevalence, clonal relationships, and risk factors. Infect Control Hosp Epidemiol 25: 405–491.
9. Lammers-Cassado J, de Lencastre H, Knipis A, Pimenta FC, Oliveira LS, et al. (2009) Molecular epidemiology and risk factors for nasal carriage of staphylococcus aureus and methicillin-resistant S. aureus in infants attending day care centers in Brazil. J Clin Microbiol 47: 3991–3997.
10. Lowy FD, Aiello AE, Bhat M, Johnson-Lawrence VA, Lee MH, et al. (2007) Staphylococcus aureus colonization and infection in New York State prisoners. J Infect Dis 196: 911–918.
11. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, et al. (2002) The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 99: 7617–7622.
12. Diep BA, Otto M (2008) The role of virulence determinants in community-associated MRSA. Trends Microbiol 16: 361–369.
13. Xiao YH, Wang J, Li Y (2008) Bacterial resistance surveillance in China: a 10-year review. J Clin Microbiol 46: 1024–1029.
14. Anthony RM, Connor AM, Power EG, French GL (1999) Use of the polymerase chain reaction for detection of the staphylococcal virulence marker Panton-Valentine leukocidin in community-acquired methicillin-resistant Staphylococcus aureus isolates from China. Diagn Microbiol Infect Dis 62: 226–229.
15. Liu QZ, Wu Q, Zhang YB, Liu MN, Hu FP, et al. (2010) Prevalence of clinical metillin-resistant Staphylococcus aureus (MRSA) with high-level mupirocin resistance in Shanghian and Wenzhou, China. Int J Antimicrob Agents 35: 114–118.
16. Wang CC, Lo WT, Chu ML, Suu LK (2004) Epidemiological typing of community-acquired methicillin-resistant Staphylococcus aureus isolates from children in Taiwan. Clin Infect Dis 39: 481–487.
17. Boyle-Vavra S, Ereshefsky B, Wang GC, Daum RS (2005) Successful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel Staphylococcal chromosome cassette mec type VT or SCCmec type IV. J Clin Microbiol 43: 4719–4730.
18. Huang YC, Hwang KP, Chen PY, Chen CJ, Lin FY (2007) Prevalence of methicillin-resistant Staphylococcus aureus nasal colonization among Taiwanese children in 2005 and 2006. J Clin Microbiol 45: 3992–3993.
19. Geng W, Yang Y, Wu D, Huang G, Wang C, et al. (2010) Molecular characteristics of community-acquired, methicillin-resistant Staphylococcus aureus isolated from Chinese children. TMS Immune Med Microbiol 36: 356–362.
20. Gomes AR, Westh H, de Lencastre H (2006) Origins and evolution of methicillin-resistant Staphylococcus aureus clonal lineages. Antimicrob Agents Chemother 50: 3277–3284.
21. Yu F, Chen Z, Liu C, Zhang X, Lin X, et al. (2000) Prevalence of Staphylococcus aureus carrying Panton-Valentine leukocidin genes among isolates from hospitalised patients in China. Clin Microbiol Infect 14: 381–384.
22. Yao D, Yu FY, Qin ZQ, Chen G, He SS, et al. (2010) Molecular characterization of Staphylococcus aureus isolates causing skin and soft tissue infections (SSTIs). BMC Infect Dis 10: 133.
23. Boyle-Vavra S, Daum RR (2007) Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 87: 3–9.
24. Fan J, Shu M, Zhang G, Zhou W, Jiang Y, et al. (2009) Biogeography and virulence of Staphylococcus aureus. PLoS One 4: e6216.
25. Lo WT, Lin WJ, Tseng MH, Wang SR, Chu ML, et al. (2008) Risk factors and molecular analysis of panton-valentine leukocidin-positive methicillin-resistant Staphylococcus aureus colonization in healthy children. Pediatr Infect Dis J 27: 707–712.
26. van Dijkeren E, Ikwawati R, Broekhuizen-Stins MJ, Jansen MD, Spalburg EC, et al. (2008) Transmission of methicillin-resistant Staphylococcus aureus strains between different kinds of pig farms. Vet Microbiol 126: 383–389.
27. Krawanek K, Metz-Gereck S, Mittermayer H (2009) Methicillin-Resistant Staphylococcus aureus ST398 from human patients, upper Austria. Emerg Infect Dis 15: 766–769.
28. van Belkum A, Melles DC, Peeters JK, van Leeuwen WB, van Dijkeren E, et al. (2006) Meticillin-resistant and susceptible Staphylococcus aureus sequence type 398 in pigs and humans. Emerg Infect Dis 14: 479–483.
29. Hallin M, De Mendoza R, Denis O, Lefort A, El Garch F, et al. (2011) Diversity of ancestry genome of human and livestock-associated ST398 methicillin resistant Staphylococcus aureus strain. Infect Genet Evol 11: 290–299.